Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) advises that it has extended the closing date of its share purchase plan (SPP) following the release today of preliminary positive DEP™ docetaxel pharmacokinetic (PK) findings from its Phase I clinical trial.

The extension is intended to provide eligible shareholders* with the opportunity to consider today’s DEP^TM docetaxel PK data announcement and the significance of these data, and in view of the existing closing date, to provide eligible shareholders with sufficient time to respond.

The SPP was due to close on Tuesday, 21 October 2014 and will now close at 5 pm (Melbourne time) on Wednesday, 29 October 2014.

Starpharma also confirms that all eligible (Australian) directors will participate in the SPP.

No action is required to be taken by shareholders who have already made application for shares under the SPP. However if you wish to increase your participation, promptly telephone Starpharma’s shareholder information line on 1300 722 706 (within Australia) or +61 3 9415 4347 (outside Australia).

The other terms of the SPP, including the price of A$0.65 per share and the maximum application value of A$15,000 per shareholder, remain as set out in the offer document mailed to shareholders on 26 September 2014.  The revised timetable of key dates for the SPP is now as follows (all times are Melbourne time):

Download ASX Announcement: Extension of Share Purchase Plan (pdf file, 81kb)